The genetic origin of drug resistance in neoplasms: implications for systemic therapy - PubMed (original) (raw)
. 1984 Sep;44(9):3643-53.
- PMID: 6744284
The genetic origin of drug resistance in neoplasms: implications for systemic therapy
J H Goldie et al. Cancer Res. 1984 Sep.
Abstract
Drug resistance continues to be a major factor in limiting the effectiveness of cancer chemotherapy. Evidence from a variety of sources implicates a genetic basis for most drug-resistant phenotypes. Assuming a random spontaneous origin for these resistant cells, it is possible to develop mathematical and computer-based models of the drug treatment of tumors. These can provide a more intuitive understanding of the basis of treatment success or failure. This in turn may lead to the development of more rational and effective treatment protocols. Studies of phenomena such as pleiotropic drug resistance are providing insights into how multiple levels of drug resistance occur and are yielding information on how certain types of drug resistance may be prevented or overcome.
Similar articles
- [Chromosomes and drug resistance of tumors].
Levina NV. Levina NV. Eksp Onkol. 1984;6(2):14-9. Eksp Onkol. 1984. PMID: 6391904 Review. Russian. - Molecular mechanisms of drug resistance.
Longley DB, Johnston PG. Longley DB, et al. J Pathol. 2005 Jan;205(2):275-92. doi: 10.1002/path.1706. J Pathol. 2005. PMID: 15641020 Review. - Modes of resistance to antitumor agents.
Kessel D. Kessel D. In Vivo. 1994 Nov-Dec;8(5):829-34. In Vivo. 1994. PMID: 7727732 Review. - Advances in cancer therapeutics: chemotherapy.
DeVita VT Jr. DeVita VT Jr. Prog Clin Biol Res. 1983;132A:47-69. Prog Clin Biol Res. 1983. PMID: 6634746 - [Resistance to chemotherapeutic agents in the treatment of cancer. Emphasizing the multiresistant phenotype].
Holte H. Holte H. Tidsskr Nor Laegeforen. 1991 Aug 20;111(19):2423-7. Tidsskr Nor Laegeforen. 1991. PMID: 1926080 Review. Norwegian.
Cited by
- Programming tumor evolution with selection gene drives to proactively combat drug resistance.
Leighow SM, Reynolds JA, Sokirniy I, Yao S, Yang Z, Inam H, Wodarz D, Archetti M, Pritchard JR. Leighow SM, et al. Nat Biotechnol. 2024 Jul 4. doi: 10.1038/s41587-024-02271-7. Online ahead of print. Nat Biotechnol. 2024. PMID: 38965430 - Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A. Ashrafizadeh M, et al. Cancer Metastasis Rev. 2024 Mar;43(1):229-260. doi: 10.1007/s10555-024-10168-9. Epub 2024 Feb 19. Cancer Metastasis Rev. 2024. PMID: 38374496 Review. - Treatment of evolving cancers will require dynamic decision support.
Strobl MAR, Gallaher J, Robertson-Tessi M, West J, Anderson ARA. Strobl MAR, et al. Ann Oncol. 2023 Oct;34(10):867-884. doi: 10.1016/j.annonc.2023.08.008. Ann Oncol. 2023. PMID: 37777307 Free PMC article. Review. - Therapeutic targeting of leukemia stem cells in acute myeloid leukemia.
Barbosa K, Deshpande AJ. Barbosa K, et al. Front Oncol. 2023 Aug 3;13:1204895. doi: 10.3389/fonc.2023.1204895. eCollection 2023. Front Oncol. 2023. PMID: 37601659 Free PMC article. Review. - Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?
Quesada S, Thomas QD, Colombo PE, Fiteni F. Quesada S, et al. Cancers (Basel). 2023 Jul 10;15(14):3556. doi: 10.3390/cancers15143556. Cancers (Basel). 2023. PMID: 37509219 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources